Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for AML: Dr. Kendra Sweet, Moffitt Cancer Center

  • Broadcast in Health
HealthTree Podcast for AML

HealthTree Podcast for AML


Follow This Show

If you liked this show, you should follow HealthTree Podcast for AML.

Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets CD123-positive AML cells. IMGN632 has shown promising results in relapsed/refractory patients in previous AML trials. 

Join us live on June 9th at 1 PM EST to learn from Dr. Kendra Sweet, an AML expert from Moffitt Cancer Center in Tampa, Florida, about IMGN632, an exciting new immunotherapy investigational agent.

During the show, Dr. Sweet will discuss what IMGN632 is, how it is helping AML patients and the current trial she is participating in that is testing IMGN632 alone, as monotherapy, or when used in combination with other frontline AML drugs. Learn all about immunotherapy and the role it can play when added to existing AML treatment modalities. There will be time at the end of the show to directly ask Dr. Sweet your questions! 

Thank you to our episode sponsor, Bristol Myers Squibb.

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled